What Daewoong does

Daewoong is a South Korean pharmaceutical manufacturer founded in 1961, headquartered in Seongnam and operating as part of the diversified Daewoong Group conglomerate. The company develops and commercializes branded pharmaceutical products across three primary domains: medical aesthetics (botulinum toxin type A products competing against Allergan's BOTOX), metabolic health (Enbloc, demonstrated in clinical studies to deliver blood sugar benefit), and regenerative medicine (through affiliate CGBio). Daewoong is one of several South Korean botulinum toxin manufacturers—alongside Hugel, Medytox, and Huons—leveraging post-2020 regulatory approvals to expand into the U.S. and China markets, where Korean products are positioned as cost-competitive alternatives to established Western brands.

The company's core technology centers on proprietary botulinum toxin type A strains and regenerative medicine capabilities, although its intellectual property position is complicated by an unresolved legal dispute with Medytox over strain ownership. CGBio, the regenerative medicine affiliate, generated $21.8M in 2025 export revenue (up 31% from $17.4M in 2024) and is the subject of a proposed divestiture to IMM Private Equity at a potential valuation of up to ~$680M. Pricing and revenue mechanics are not publicly disclosed, but industry data suggests Korean botulinum toxin products target materially lower per-unit pricing than incumbent Western brands.

Business model is that of a branded pharmaceutical manufacturer selling finished-dose products through distribution channels to healthcare providers (aesthetic practitioners, endocrinologists, hospitals) and ultimately patients. The company has no disclosed direct-to-consumer or subscription revenue model. Customer segments are identified primarily as medical aesthetic practitioners and patients in the U.S. and China. Recent corporate actions include the Enbloc product launch (2026-06), the CGBio divestiture (announced 2026-03-06), and an exchange agreement with Aeon Biopharma (2025-12-15), suggesting active portfolio reshaping.

Name

Daewoong

Website

https://daewoongholdings.com

Company type

Private

Founded year

1961

Operating status

Operating

Headcount range

251–500 employees

Short description

Daewoong is a South Korean pharmaceutical manufacturer (founded 1961, Seongnam) producing botulinum toxin type A aesthetics products, metabolic health drug Enbloc, and regenerative medicine via affiliate CGBio for global healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Pharmaceutical manufacturing
• Botulinum toxin products
• Medical aesthetics
• Regenerative medicine
• Metabolic pharmaceuticals

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Core offering

Daewoong manufactures and sells pharmaceutical products, with a primary focus on botulinum toxin type A for aesthetic and therapeutic applications. The company also produces metabolic health pharmaceuticals (Enbloc) for blood sugar management and operates in regenerative medicine through its affiliate CGBio. Daewoong competes in global markets including South Korea, the United States, and China.

Product overview

Daewoong is a South Korean pharmaceutical and biotechnology company with a diversified portfolio spanning metabolic pharmaceuticals (Enbloc for blood sugar management), medical aesthetics (botulinum toxin type A products), and regenerative medicine (through affiliate CGBio). The company competes in the global botulinum toxin market alongside Hugel and Medytox, and is expanding into the U.S. and China markets.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered minor and core.

• Aeon BiopharmaminorStrategic or Co-development Partner · 15 December 2025Aeon Biopharma announced the execution of an exchange agreement with Daewoong. Details of the partnership scope and nature of collaboration were not fully disclosed in available sources.
• CGBiocoreOthersCGBio is Daewoong Group's regenerative medicine affiliate. It has experienced 31% annual export growth, reaching $21.8 million in 2025 from $17.4 million in 2024. Daewoong is divesting this affiliate to IMM Private Equity.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• AbbVie (BOTOX): AbbVie owns BOTOX (Allergan Aesthetics), the global market leader in botulinum toxin type A. It is the broad incumbent whose pricing power and brand equity Daewoong and other Korean manufacturers are attempting to disrupt.
• Galderma: Galderma is a global aesthetics leader (fillers, skincare, and emerging toxin plays). It is a broad incumbent that competes for the same aesthetic practitioner and patient demand that Daewoong targets.
• Eli Lilly: Eli Lilly is a leader in metabolic pharmaceuticals (Mounjaro, Zepbound, diabetes portfolio). It serves as a benchmark broad incumbent for evaluating the commercial opportunity for Daewoong's Enbloc in cardiometabolic indications.
• Novo Nordisk: Novo Nordisk is the global leader in diabetes/obesity therapeutics (Ozempic, Wegovy). It is relevant as a benchmark incumbent in the cardiometabolic/metabolic health category where Daewoong's Enbloc operates.
• Ipsen (Dysport): Ipsen markets Dysport, a competing botulinum toxin type A product in aesthetics and therapeutics. It is a broad incumbent competing globally with Daewoong's franchise.

Direct peers

• Hugel: Hugel is a direct Korean competitor in botulinum toxin type A (product: Botulax) and also operates in aesthetics and therapeutics. It competes head-to-head with Daewoong in Korea, China, and the planned U.S. expansion, with comparable pricing strategy.
• Medytox: Medytox is a direct Korean competitor in botulinum toxin (product: Neuronox) and is currently engaged in a legal dispute with Daewoong over botulinum toxin strain ownership. Operates in similar aesthetics and therapeutic indications.
• Huons: Huons is another South Korean manufacturer of botulinum toxin (product: Hutox) and a direct peer in the domestic and international Korean aesthetics market, pursuing similar export-led growth strategies.

Emerging players

• Evolus: Evolus markets Jeuveau, a competing aesthetic-only botulinum toxin in the U.S. It is an emerging player targeting the same value-based positioning that Daewoong plans to pursue in the U.S. aesthetics market.
• Aeon Biopharma: Aeon Biopharma has a recent exchange agreement with Daewoong and operates in the botulinum toxin therapeutic space. It is an emerging participant with partial overlap to Daewoong's aesthetic and therapeutic toxin development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daewoong